6th Annual Pharma Packaging and Labeling USA 201426-27 February 2014, Philadelphia, USA
The 6th year of a truly successful and respected Pharma Packaging and Labeling event is rolling back into town with this year expected to be bigger than ever.
With key legislation on the horizon in California and the counterfeiting market now worth millions of dollars as well as sustainability and green packaging in demand, the need for this event is heightened.
We aim to bring you more compelling speakers talking about the subjects that matter to you. Following extensive research into the market we have been able identify key themes to discuss, issues to debate and people you want to meet all under one roof.
This outstanding event will provide a fantastic opportunity for exhibitors to promote their products and services to senior level decision makers from the region. Exhibition spaces are filling up due to the success of last year’s event as well as the global reputation of this world-renowned series.
Pharma Packaging and Labeling 2014 aims to target specific areas of the market in an interesting and insightful manner.
Rondo Pak would like to welcome all attendees of Pharma Packaging and Labeling to their drink reception taking place at the end of day one, on the 26th of February.
Eli Lilly has obtained US Food and Drug Administration approval for its Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on …
The US Food and Drug Administration (FDA) has granted orphan drug designation for Bayer HealthCare's investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) to treat patients with non-cystic fibrosis bronchiectasis (NCFB).
US-based Pfizer may push ahead with a second approach for the takeover of UK-based AstraZeneca after the company reportedly rejected its initial £60bn ($101bn) bid.
Canada-based Valeant Pharmaceuticals and US-based Pershing Square Capital Management have disclosed details of their offer to purchase Botox-maker Allergan for more than $45bn.
GlaxoSmithKline (GSK) and Genmab have obtained US Food and Drug Administration (FDA) approval for Arzerra (ofatumumab) as first-line treatment in combination with chlorambucil for patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine…